Navigation Links
Abaxis Receives Presidential "E" Award for Exports
Date:5/16/2011

UNION CITY, Calif., May 16, 2011 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today announced the Company was awarded the Presidential "E" Award for Exports by U.S. Department of Commerce Secretary Gary Locke at the Department's headquarters in Washington, D.C.  The "E" Awards are the highest recognition any U.S. entity may receive for making a significant contribution to the expansion of U.S. exports.

"Exporting continues to be a significant part of our sales growth and we are honored to receive the "E" Award," said Clint Severson, chairman and chief executive officer of Abaxis. Since 2006, which encompasses one of the most challenging macro-economic periods in the history of the United States, Abaxis' annual exports have grown at a compounded rate of 21 percent.

Abaxis, Inc. is a Union City, California developer, manufacturer and marketer of portable blood chemistry analyzers for use in the human healthcare and veterinary markets to provide clinicians with rapid blood constituent measurements.  Abaxis provides leading-edge technology, tools and services that support best medical practices, enabling physicians and veterinarians to respond to the health needs of their clients at the point-of-care while operating economical and profitable practices.

"Exports are a key driver of America's economic recovery," said Secretary of Commerce Gary Locke.  "President Obama's National Export Initiative (NEI), which aims to double U.S. exports by 2015 in support of several million American jobs, is a robust, forward-looking trade agenda with an emphasis on domestic job growth.  Abaxis, Inc. is being honored today for making significant contributions toward fulfilling that agenda."

"I congratulate you on your significant export achievement. It is businesses like yours that will help us meet or exceed the President's NEI goals. Your firm provides an example we hope more American companies will follow," Locke added.

A business client of the Department's U.S. Commercial Service, Abaxis has benefited from export counseling, trade shows, market research, and business matchmaking to greatly expand its export sales.  Currently, Abaxis exports to 33 different countries, a list that continues to expand every year. This allows a substantial increase in the volume of exports over a four-year period, a major criteria for the award.

U.S. companies are nominated for the "E" Awards through the U.S. Commercial Service office network in 108 U.S. cities and more than 75 countries which helps U.S. companies export. Criteria for the award is based on four years of successive export growth, usually accompanied by a rising percentage of export sales within total sales. An applicant's demonstration of an innovative international marketing plan that led to the increase in exports is a significant factor in making the award.

All nominations are reviewed by the "E" Award Committee, which is chaired by the Department of Commerce, and includes representatives from ExIm Bank, and the Departments of Labor, State, and Transportation.

President Kennedy revived the World War II "E" symbol of excellence to honor and provide recognition to America's exporters. Thus, the "E" Award Program was established by Executive Order 10978 on December 5, 1961.

A total of 27 U.S. companies were presented with the "E" Award at the May 16, 2011 World Trade Week ceremonies in Washington DC.

About AbaxisAbaxis develops, manufactures, markets and sells portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements.  The system consists of a compact, 5.1 kilograms (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients.  The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples.  The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.  

This press release includes,  statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations.  Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act.  These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts.  Specific forward-looking statements contained in this press release  may be affected by risks and uncertainties, including, but not limited to, those related to losses or system failures with respect to Abaxis' facilities or manufacturing operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis' products and the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties, risks related to condition of the United States economy and other risks detailed under "Risk Factors" in Abaxis' Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2010 and Abaxis' other periodic reports filed from time to time with the United States Securities and Exchange Commission.  Forward-looking statements speak only as of the date the statements were made.  Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.  Contact:

Clint Severson

Lytham Partners, LLCChief Executive Officer

Joe Dorame, Robert Blum and Joe DiazAbaxis, Inc.

602-889-9700510-675-6500
'/>"/>

SOURCE Abaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ABAXIS Announces Launch of the First Fully Automated Canine Wellness Profile That Includes a Canine Heartworm Antigen Test
2. Abaxis to Report Second Quarter Fiscal 2010 Financial Results Tuesday, October 27, 2009
3. Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010
4. Abaxis, Inc. to Present at the Sidoti & Company Second Annual New York Institutional Investor Forum
5. Abaxis, Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Abaxis, Inc. to Present at Sidoti & Companys Ninth Annual West Coast Institutional Investor Forum
7. Abaxis to Report Second Quarter Fiscal 2011 Financial Results Tuesday, October 26, 2010
8. Abaxis Reports Financial Performance with Record Sales for the Second Quarter of Fiscal 2011
9. Abaxis, Inc. to Present at Stephens Fall Investment Conference
10. Abaxis Increases Reagent Disc Offering for Physician Office Market With Release of BioChemistry Panel Plus
11. Abaxis to Report Third Quarter Fiscal 2011 Financial Results Thursday, January 27, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology:
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
Breaking Medicine News(10 mins):